メニエール病治療薬の世界市場2022

【英語タイトル】Meniere Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Global Markets Directが出版した調査資料(GMDHC22115IDB)・商品コード:GMDHC22115IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2022年3月
・ページ数:38
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥296,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥888,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、開発中のメニエール病治療薬市場について調査・分析し、メニエール病概要、治療薬開発、パイプライン概要、企業別のパイプライン、企業別の開発中製品、治療薬分析、標的別分析、作用機序別分析、投与経路別分析、分子タイプ別分析、治療薬開発に携わる企業など、以下の項目を掲載しております。
・メニエール病-概要
・メニエール病-治療薬開発
・パイプライン概要
・企業別のパイプライン
・企業別の開発中製品
・メニエール病-治療薬分析
・標的別分析
・作用機序別分析
・投与経路別分析
・分子タイプ別分析
・メニエール病-治療薬開発に携わる企業
【レポートの概要】

Meniere Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Meniere Disease – Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Meniere Disease (Ear Nose Throat Disorders) pipeline landscape.

Meniere disease is a disorder of the inner ear that causes spontaneous episodes of vertigo. Signs and symptoms of Meniere disease are hearing loss, tinnitus and feeling of fullness in the ear. Causes include allergies, viral infection, head trauma and migraines.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Meniere Disease – Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Meniere Disease (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meniere Disease (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 1, 3, 2 and 1 respectively.

Meniere Disease (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Meniere Disease (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Meniere Disease (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Meniere Disease (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Meniere Disease (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Meniere Disease (Ear Nose Throat Disorders)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Meniere Disease (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Meniere Disease (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Meniere Disease – Overview
Meniere Disease – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Meniere Disease – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Meniere Disease – Companies Involved in Therapeutics Development
Adare Pharma Solutions
Apsen Farmaceutica SA
IntraBio Ltd
Quark Pharmaceuticals Inc
Sound Pharmaceuticals Inc
Spiral Therapeutics Inc
Steel Therapeutics Inc
Synphora AB
Meniere Disease – Drug Profiles
APSLXR – Drug Profile
Product Description
Mechanism Of Action
betamethasone valerate ER – Drug Profile
Product Description
Mechanism Of Action
History of Events
dexamethasone – Drug Profile
Product Description
Mechanism Of Action
Drug for Meniere’s Disease – Drug Profile
Product Description
Mechanism Of Action
ebselen – Drug Profile
Product Description
Mechanism Of Action
History of Events
IB-2000s – Drug Profile
Product Description
Mechanism Of Action
latanoprost – Drug Profile
Product Description
Mechanism Of Action
History of Events
QPI-1017 – Drug Profile
Product Description
Mechanism Of Action
Meniere Disease – Dormant Projects
Meniere Disease – Product Development Milestones
Featured News & Press Releases
Jun 08, 2020: Sound Pharma advances pivotal Phase 3 clinical trials in Meniere’s Disease
Sep 18, 2019: FDA grants Fast Track Designation for SPI-1005 in the treatment of Meniere’s Disease
Jun 25, 2019: Sound Pharmaceuticals announces positive topline results from the SPI-1005 Phase 2b Meniere’s Disease clinical trial
Mar 20, 2019: Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere’s Disease clinical trial
Mar 06, 2019: Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere’s Disease clinical trial
Oct 03, 2017: Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Menieres Disease
Jun 27, 2017: Sound Pharmaceuticals completes enrollment on Meniere’s Disease clinical trial
Mar 20, 2017: Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use
Jan 05, 2016: FDA allows Sound Pharmaceuticals to begin Meniere Disease clinical trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Meniere Disease, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Meniere Disease - Pipeline by Adare Pharma Solutions, 2022
Meniere Disease - Pipeline by Apsen Farmaceutica SA, 2022
Meniere Disease - Pipeline by IntraBio Ltd, 2022
Meniere Disease - Pipeline by Quark Pharmaceuticals Inc, 2022
Meniere Disease - Pipeline by Sound Pharmaceuticals Inc, 2022
Meniere Disease - Pipeline by Spiral Therapeutics Inc, 2022
Meniere Disease - Pipeline by Steel Therapeutics Inc, 2022
Meniere Disease - Pipeline by Synphora AB, 2022
Meniere Disease - Dormant Projects, 2022

List of Figures
Number of Products under Development for Meniere Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

★調査レポート[メニエール病治療薬の世界市場2022] (コード:GMDHC22115IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[メニエール病治療薬の世界市場2022]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆